OncLive® On Air S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
Jan 30, 2026
Heather McArthur, a medical oncologist and breast cancer trialist, discusses PARP inhibitors, immune checkpoint inhibitors, and TROP2-targeting antibody–drug conjugates for metastatic triple-negative breast cancer. She outlines pivotal trials, next-generation agents, combinations of ADCs with PARP or PD-1 therapies, and practical toxicity management and sequencing considerations.
AI Snips
Chapters
Transcript
Episode notes
PARP Inhibitors Improve PFS And QoL
- PARP inhibitors (olaparib, talazoparib) improved PFS and quality of life versus chemotherapy in BRCA-associated advanced breast cancer.
- Next-generation PARP1-selective agents show promising responses and potentially lower toxicity profiles.
ADC + PARP May Broaden Benefit Beyond BRCA
- Combining ADCs with PARP inhibitors might overcome the need for germline BRCA mutations and broaden benefit across patients.
- This combination is an emerging strategy worth further clinical evaluation.
Pembrolizumab Yields Meaningful OS Gain
- Pembrolizumab plus chemotherapy (KEYNOTE-355) improved PFS and gave a seven-month OS benefit in PD-L1 CPS ≥10 metastatic TNBC.
- In a disease with median survival ~12–18 months, a seven-month OS gain is clinically meaningful.